ZENEO® Terbutaline : Treatment for severe asthma crisis
Worldwide, there are approximately 235 million people suffering from asthma with 383,000 annual deaths attributed to the disease. Most of them are preventable (1). Furthermore, 10 % of asthma patients suffer from acute form of asthma (2).
Mild asthma sufferers carry metered-dose inhaler to deal with asthma crisis, moderate to severe asthma patients use inhaler spacer or nebulizer in case of exacerbation. Despite this, every day in America 5,000 people visit an emergency room due to asthma crisis, 1,000 are admitted to hospital and 11 die leading to an annual basis of more than 4,000 deaths due to Asthma (3).
Europe is also highly affected by Asthma with around 15,000 people dying each year from asthma attacks (4).
Today, in the case of asthma exacerbation, the standard of care is to firstly use a spacer inhaler (which consists of an MDI with an additional spacer) before going to an emergency department, they are often bulky and it is hard to know if the measured dose has fully reached the patient. Terbutaline is used in the case of severe exacerbation when patients are not responding to treatments with inhaled beta-agonist or other established therapies.
ZENEO® Terbutaline will change the way severe asthma is treated, improve patients’ quality of life and save lives.
(1)http://www.who.int/mediacentre/ factsheets/ fs307/ en/ (accessed 19/9/2017)
(2) The prevalence of severe refractory asthma, The American Academy of Allergy Asthma and Immunology, https://www.aaaai.org/global/latest-research-summaries/New-Research-from-JACI-In-Practice/refractory-asthma (accessed 19/9/2017)
(4) Calculated from data in the European Respiratory Society White Book (2nd Ed) 2012. Asthma in Adults (P. Cullinan & F Chung)
When experiencing a severe asthma crisis, the patient can self-administer ZENEO® Terbutaline in the thigh.
Another person could also administer the product for the patient, in a ventrogluteal injection.